Abstract Library

#4449 Treatment of MiNEN with peptide receptor radionuclide therapy

Introduction: Mixed non-neuroendocrine and neuroendocrine neoplasms (MiNENs) of gastrointestinal tract are rare tumours with characteristic histological features include at least 30% of both neuroendocrine and non-neuroendocrine components of the whole neoplasm. They are usually treated with surgical resection and chemotherapy in advanced disease. However, there is scarcity of data for the use of peptide receptor radionuclide therapy (PRRT) in these tumours.

Conference:

Presenting Author: Shekhda K

Authors: Shekhda K, Luong T, Paterson A, Navalkissoor S, Krell D,

Keywords: MiNEN, PRRT, DOTATATE,

#4322 Clinical outcomes of patients with rectal neuroendocrine tumours smaller than 10mm after endoscopic resection

Introduction: Rectal neuroendocrine tumours (r-NETs) generally have a good prognosis, but up to 20% may be misdiagnosed during endoscopy, risking inadequate treatment. Prognosis factors include tumour size, grading, staging, and lymphovascular invasion, with guidelines recommending endoscopic resection for small, low-grade lesions.

Conference:

Presenting Author:

Authors: Dell' Unto E, Riding G, Rimondi A, Panzuto F, Luong T,

Keywords: Rectal Carcinoid, Rectal Neuroendocrine Tumour, Endoscopic Resection,

#3958 Treatment strategy for pancreatic NETs smaller than 2 cm should be based on the diagnosis of malignancy as well – New treatment strategy for small pancreatic NETs

Introduction: There are still many unclear issues regarding the treatment of non-functioning small (≤20 mm) pancreatic neuroendocrine neoplasms (pNENs).

Conference:

Presenting Author: Hijioka S

Authors: Hijioka S, Yamashige D, Esaki M, Honda G, Masui T,

Keywords: small pancreatic neuroendocrine neoplasm, tumor size, grading, treatment strategy, Japanese cohort,

#3537 177Lu-DOTATATE (PRRT) in the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs) versus other tumors

Introduction: 177Lu-DOTATATE (PRRT) treatment is indicated in Spain in GEPNET but its activity in other somatostatin receptor-positive tumors is known.

Conference:

Presenting Author: Jimenez-Fonseca P

Authors: Jimenez-Fonseca P, Pubul V, Belló P, Riesco-Martinez M, Aller J,

Keywords: PRRT, NET, Somatostatin receptor-positive tumor, Survival,

#3386 Peptide Radio Receptor Therapy induces immune activation in patients with neuroendocrine tumors and might sensitize to immunotherapy

Introduction: Peptide Radio Receptor Therapy (PRRT) is a standard treatment in patients with neuroendocrine tumors (NET), but treatment responses are limited and novel therapy combinations are needed. Since radiation induced cell death is considered immunogenic, patients might benefit from a combination of PRRT with immunotherapies, such as immune checkpoint inhibitors (ICI).

Conference:

Presenting Author: Büttner S

Authors: Büttner S, Detjen K, Galler M, Siefert J, Wiedenmann B,

Keywords: NET, PRRT, checkpoint inhibitors, immune response, PD1, flow cytometry,